US2005176690A1PendingUtilityA1

Method for treatment of reactive arthritis or bursitis

51
Priority: Mar 17, 1999Filed: Feb 4, 2005Published: Aug 11, 2005
Est. expiryMar 17, 2019(expired)· nominal 20-yr term from priority
Inventors:Ernest L. Bonner, Jr.Robert Hines
A61P 27/02A61P 19/02A61K 31/4164A61K 31/522A61K 31/198A61P 15/00A61K 31/4406A61P 13/08A61K 31/65A61P 13/02
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for treatment for conditions in human beings associated with either or both reactive arthritis or bursitis comprising administering a combination of member of the family of synthetic purine nucleoside analog antiviral drugs, a member of the tetracycline family, and a member of the nitroimidazole family, or alternatively, administering a combination of a member of the family of synthetic purine nucleoside analog antiviral drugs, a member of the quinolone family, and a member of the nitroimidazole family.

Claims

exact text as granted — not AI-modified
1 . A method for medically treating the symptoms of reactive arthritis or bursitis in humans comprising: 
 administering to a patient an effective amount of the combination of a member of the family of synthetic purine nucleoside analog antiviral drugs or a pharmaceutically acceptable ester or a metabolite thereof, a member of the tetracycline family or a metabolite thereof, and a member of the nitroimidazole family or a metabolite thereof.    
     
     
         2 . The method for treatment of  claim 1  wherein: 
 said member of the family of synthetic purine nucleoside analog antiviral drugs comprises acyclovir.    
     
     
         3 . The method for treatment of  claim 1  wherein: 
 said member of the family of synthetic purine nucleoside analog antiviral drugs comprises valacyclovir.    
     
     
         4 . The method for treatment of  claim 1  wherein: 
 said member of the tetracycline family comprises minocycline hydrochloride.    
     
     
         5 . The method for treatment of  claim 1  wherein: 
 said member of the nitroimidazole family comprises metronidazole.    
     
     
         6 . The method for treatment of  claim 1  wherein: 
 said member of the family of synthetic purine nucleoside analog antiviral drugs comprises acyclovir or a pharmaceutically acceptable ester thereof, said member of the tetracycline family comprises minocycline hydrochloride, and said member of the nitroimidazole family comprises metronidazole.    
     
     
         7 . The treatment of  claim 6  wherein: 
 between approximately 50 to 200 mg of minocycline hydrochloride are administered.    
     
     
         8 . The treatment of  claim 6  wherein: 
 between approximately 100 mg to 4 gm of acyclovir are administered.    
     
     
         9 . The treatment of  claim 6  wherein: 
 between approximately 100 mg to 1 gm of metronidazole are administered.    
     
     
         10 . The treatment of  claim 6  wherein: 
 between approximately 100 mg to 4 gm of acyclovir are administered, between approximately 50 to 200 mg of minocycline hydrochloride are administered, and between approximately 100 mg to 1 gm of metronidazole are administered.    
     
     
         11 . The treatment of  claim 6  wherein: 
 approximately 400 mg of acyclovir are administered twice daily.    
     
     
         12 . The treatment of  claim 6  wherein: 
 approximately 100 mg of minocycline hydrochloride are administered twice daily.    
     
     
         13 . The treatment of  claim 6  wherein: 
 approximately 250 mg of metronidazole are administered twice daily.    
     
     
         14 . The treatment of  claim 6  wherein: 
 approximately 400 mg of acyclovir are administered twice daily, approximately 100 mg of minocycline hydrochloride are administered twice daily, and approximately 250 mg of metronidazole are administered twice daily.    
     
     
         15 . The method for treatment of  claim 1  wherein: 
 said member of the family of synthetic purine nucleoside analog antiviral drugs comprises valacyclovir or a pharmaceutically acceptable ester thereof, said member of the tetracycline family comprises minocycline hydrochloride, and said member of the nitroimidazole family comprises metronidazole.    
     
     
         16 . The treatment of  claim 15  wherein: 
 between approximately 125 mg to 4 gm of valacyclovir hydrochloride are administered daily.    
     
     
         17 . The treatment of  claim 15  wherein: 
 between approximately 50 to 200 mg of minocycline hydrochloride are administered daily.    
     
     
         18 . The treatment of  claim 15  wherein: 
 between approximately 100 mg to 1 gm of metronidazole are administered daily.    
     
     
         19 . The treatment of  claim 15  wherein: 
 between approximately 125 mg to 4 gm of valacyclovir hydrochloride are administered daily, between approximately 50 to 200 mg of minocycline hydrochloride are administered daily, and between approximately 100 mg to 1 gm of metronidazole are administered daily.    
     
     
         20 . The treatment of  claim 15  wherein: 
 approximately 500 mg of valacyclovir hydrochloride are administered twice daily.    
     
     
         21 . The treatment of  claim 15  wherein: 
 approximately 100 mg of minocycline hydrochloride are administered twice daily.    
     
     
         22 . The treatment of  claim 15  wherein: 
 approximately 250 mg of metronidazole are administered twice daily.    
     
     
         23 . The treatment of  claim 15  wherein: 
 approximately 500 mg of valacyclovir hydrochloride are administered twice daily, approximately 100 mg of minocycline hydrochloride are administered twice daily, and approximately 250 mg of metronidazole are administered twice daily.    
     
     
         24 . A method for medically treating the symptoms of reactive arthritis or bursitis in humans comprising: 
 administering to a patient an effective amount of the combination of a member of the family of synthetic purine nucleoside analog antiviral drugs or a pharmaceutically acceptable ester or a metabolite thereof, a member of the quinolone family or a metabolite thereof, and a member of the nitroimidazole family or a metabolite thereof.    
     
     
         25 . The method for treatment of  claim 24  wherein: 
 said member of the family of synthetic purine nucleoside analog antiviral drugs comprises acyclovir.    
     
     
         26 . The method for treatment of  claim 24  wherein: 
 said member of the family of synthetic purine nucleoside analog antiviral drugs comprises valacyclovir hydrochloride.    
     
     
         27 . The method for treatment of  claim 24  wherein: 
 said member of the quinolone family comprises Ciprofloxacin.    
     
     
         28 . The method for treatment of  claim 24  wherein: 
 said member of the nitroimidazole family comprises metronidazole.    
     
     
         29 . The method for treatment of  claim 1  wherein: 
 said member of the family of synthetic purine nucleoside analog antiviral drugs comprises acyclovir or a pharmaceutically acceptable ester thereof, said member of the quinolone family comprises Ciprofloxacin, and said member of the nitroimidazole family comprises metronidazole.    
     
     
         30 . The treatment of  claim 29  wherein: 
 between approximately 50 mg to 2 gm of Ciprofloxacin are administered.    
     
     
         31 . The treatment of  claim 29  wherein: 
 between approximately 100 mg to 4 gm of acyclovir are administered.    
     
     
         32 . The treatment of  claim 29  wherein: 
 between approximately 100 mg to 1 gm of metronidazole are administered.    
     
     
         33 . The treatment of  claim 29  wherein: 
 between approximately 100 mg to 4 gm of acyclovir are administered, between approximately 50 mg to 2 gm of Ciprofloxacin are administered, and between approximately 100 mg to 1 gm of metronidazole are administered.    
     
     
         34 . The treatment of  claim 29  wherein: 
 approximately 400 mg of acyclovir are administered twice daily.    
     
     
         35 . The treatment of  claim 29  wherein: 
 approximately 500 mg of Ciprofloxacin are administered twice daily.    
     
     
         36 . The treatment of  claim 29  wherein: 
 approximately 250 mg of metronidazole are administered twice daily.    
     
     
         37 . The treatment of  claim 29  wherein: 
 approximately 400 mg of acyclovir are administered twice daily, approximately 500 mg of Ciprofloxacin are administered twice daily, and approximately 250 mg of metronidazole are administered twice daily.    
     
     
         38 . The method for treatment of  claim 24  wherein: 
 said member of the family of synthetic purine nucleoside analog antiviral drugs comprises valacyclovir or a pharmaceutically acceptable ester thereof, said member of the quinolone family comprises Ciprofloxacin, and said member of the nitroimidazole family comprises metronidazole.    
     
     
         39 . The treatment of  claim 38  wherein: 
 between approximately 125 mg to 4 gm of valacyclovir hydrochloride are administered daily.    
     
     
         40 . The treatment of  claim 38  wherein: 
 between approximately 50 mg to 2 gm of Ciprofloxacin are administered daily.    
     
     
         41 . The treatment of  claim 38  wherein: 
 between approximately 100 mg to 1 gm of metronidazole are administered daily.    
     
     
         42 . The treatment of  claim 38  wherein: 
 between approximately 125 mg to 4 gm of valacyclovir hydrochloride are administered daily, between approximately 50 mg to 2 gm of Ciprofloxacin are administered daily, and between approximately 100 mg to 1 gm of metronidazole are administered daily.    
     
     
         43 . The treatment of  claim 38  wherein: 
 approximately 500 mg of valacyclovir hydrochloride are administered twice daily.    
     
     
         44 . The treatment of  claim 38  wherein: 
 approximately 500 mg of Ciprofloxacin are administered twice daily.    
     
     
         45 . The treatment of  claim 38  wherein: 
 approximately 250 mg of metronidazole are administered twice daily.    
     
     
         46 . The treatment of  claim 38  wherein: 
 approximately 500 mg of valacyclovir hydrochloride are administered twice daily, approximately 500 mg of Ciprofloxacin are administered twice daily, and approximately 250 mg of metronidazole are administered twice daily.    
     
     
         47 . The method for treatment of  claim 24  wherein: 
 said member of the family of synthetic purine nucleoside analog antiviral drugs comprises acyclovir or a pharmaceutically acceptable ester thereof, said member of the quinolone family comprises a fluoroquinolone, and said member of the nitroimidazole family comprises metronidazole.    
     
     
         48 . The treatment of  claim 29  wherein: 
 said pharmaceutically acceptable ester of acyclovir is valacyclovir hydrochloride.    
     
     
         49 . The treatment of  claim 48  wherein: 
 between approximately 125 mg to 4 gm of valacyclovir hydrochloride are administered daily.    
     
     
         50 . The treatment of  claim 48  wherein: 
 between approximately 125 mg to 4 gm of valacyclovir hydrochloride are administered, between approximately 50 mg to 2 gm of Ciprofloxacin are administered, and between approximately 100 mg to 1 gm of metronidazole are administered.    
     
     
         51 . The treatment of  claim 48  wherein: 
 approximately 500 mg of valacyclovir hydrochloride are administered twice daily.    
     
     
         52 . A method for medically treating the symptoms of reactive arthritis or bursitis in humans comprising: 
 administering to a patient an effective amount of the combination of a member of the family of synthetic purine nucleoside analog antiviral drugs or a pharmaceutically acceptable ester or a metabolite thereof, and a member of the tetracycline family or a metabolite thereof.    
     
     
         53 . The method for treatment of  claim 52  wherein: 
 said member of the family of synthetic purine nucleoside analog antiviral drugs comprises acyclovir.    
     
     
         54 . The treatment of  claim 53  wherein: 
 between approximately 100 mg to 4 gm of acyclovir are administered.    
     
     
         55 . The treatment of  claim 54  wherein: 
 approximately 400 mg of acyclovir are administered twice daily.    
     
     
         56 . The method for treatment of  claim 52  wherein: 
 said member of the family of synthetic purine nucleoside analog antiviral drugs comprises valacyclovir hydrochloride.    
     
     
         57 . The treatment of  claim 56  wherein: 
 between approximately 125 mg to 4 gm of valacyclovir hydrochloride are administered daily.    
     
     
         58 . The treatment of  claim 57  wherein: 
 approximately 500 mg of valacyclovir hydrochloride are administered twice daily.    
     
     
         59 . The method for treatment of  claim 52  wherein: 
 said member of the tetracycline family comprises minocycline hydrochloride.    
     
     
         60 . The treatment of  claim 59  wherein: 
 between approximately 50 to 200 mg of minocycline hydrochloride are administered.    
     
     
         61 . The treatment of  claim 60  wherein: 
 approximately 100 mg of minocycline hydrochloride are administered twice daily.    
     
     
         62 . A method for medically treating the symptoms of reactive arthritis or bursitis in humans comprising: 
 administering to a patient an effective amount of the combination of a member of the family of synthetic purine nucleoside analog antiviral drugs or a pharmaceutically acceptable ester or a metabolite thereof, and a member of the quinolone family or a metabolite thereof.    
     
     
         63 . The method for treatment of  claim 62  wherein: 
 said member of the family of synthetic purine nucleoside analog antiviral drugs comprises acyclovir.    
     
     
         64 . The treatment of  claim 63  wherein: 
 between approximately 100 mg to 4 gm of acyclovir are administered.    
     
     
         65 . The treatment of  claim 64  wherein: 
 approximately 400 mg of acyclovir are administered twice daily.    
     
     
         66 . The method for treatment of  claim 62  wherein: 
 said member of the family of synthetic purine nucleoside analog antiviral drugs comprises valacyclovir hydrochloride.    
     
     
         67 . The treatment of  claim 66  wherein: 
 between approximately 125 mg to 4 gm of valacyclovir hydrochloride are administered daily.    
     
     
         68 . The treatment of  claim 67  wherein: 
 approximately 500 mg of valacyclovir hydrochloride are administered twice daily.    
     
     
         69 . The method for treatment of  claim 62  wherein: 
 said member of the quinolone family comprises Ciprofloxacin.    
     
     
         70 . The treatment of  claim 69  wherein: 
 between approximately 50 mg to 2 gm of Ciprofloxacin are administered.    
     
     
         71 . The treatment of  claim 70  wherein: 
 approximately 500 mg of Ciprofloxacin are administered twice daily.

Join the waitlist — get patent alerts

Track US2005176690A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.